Researchers are the first to create sensory interneurons from stem cells
Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have, for the first time, coaxed human stem cells to become sensory interneurons — the cells that give us our sense of touch. The new protocol could be a step toward stem cell–based therapies to restore sensation in paralyzed people who have lost feeling in parts of their body.
The study, which was led by Samantha Butler, a UCLA associate professor of neurobiology and member of the Broad Stem Cell Research Center, was published today in the journal Stem Cell Reports.
Sensory interneurons, a class of neurons in the spinal cord, are responsible for relaying information from throughout the body to the central nervous system, which enables the sense of touch. The lack of a sense of touch greatly affects people who are paralyzed. For example, they often cannot feel the touch of another person, and the inability to feel pain leaves them susceptible to burns from inadvertent contact with a hot surface.
“The field has for a long time focused on making people walk again,” said Butler, the study’s senior author. “‘Making people feel again doesn’t have quite the same ring. But to walk, you need to be able to feel and to sense your body in space; the two processes really go hand in glove.”
In a separate study, published in September by the journal eLife, Butler and her colleagues discovered how signals from a family of proteins called bone morphogenetic proteins, or BMPs, influence the development of sensory interneurons in chicken embryos. The Stem Cell Reports research applies those findings to human stem cells in the lab.
When the researchers added a specific bone morphogenetic protein called BMP4, as well as another signaling molecule called retinoic acid, to human embryonic stem cells, they got a mixture of two types of sensory interneurons. DI1 sensory interneurons give people proprioception — a sense of where their body is in space — and dI3 sensory interneurons enable them to feel a sense of pressure.
The researchers found the identical mixture of sensory interneurons developed when they added the same signaling molecules to induced pluripotent stem cells, which are produced by reprogramming a patient’s own mature cells such as skin cells. This reprogramming method creates stem cells that can create any cell type while also maintaining the genetic code of the person they originated from. The ability to create sensory interneurons with a patient’s own reprogrammed cells holds significant potential for the creation of a cell-based treatment that restores the sense of touch without immune suppression.
Butler hopes to be able to create one type of interneuron at a time, which would make it easier to define the separate roles of each cell type and allow scientists to start the process of using these cells in clinical applications for people who are paralyzed. However, her research group has not yet identified how to make stem cells yield entirely dI1 or entirely dI3 cells — perhaps because another signaling pathway is involved, she said.
The researchers also have yet to determine the specific recipe of growth factors that would coax stem cells to create other types of sensory interneurons.
The group is currently implanting the new dI1 and dI3 sensory interneurons into the spinal cords of mice to understand whether the cells integrate into the nervous system and become fully functional. This is a critical step toward defining the clinical potential of the cells.
“This is a long path,” Butler said. “We haven’t solved how to restore touch but we’ve made a major first step by working out some of these protocols to create sensory interneurons.”
Learn more: UCLA scientists make cells that enable the sense of touch
The Latest on: Stem cell–based therapies
[google_news title=”” keyword=”stem cell–based therapies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Stem cell–based therapies
- Charles River to help FibroBiologics produce 3D cell-based therapieson May 2, 2024 at 10:00 pm
FibroBiologics is developing CYMS101, a fibroblast cell therapy made of human skin fibroblasts that's shown promise in preclinical studies.
- Buy Rating on BioRestorative Therapies: Innovative Cell-based Therapies and Strategic Growth Opportunitieson May 2, 2024 at 9:15 am
Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on BioRestorative Therapies (BRTX – Research Report), reducing the ...
- Stem Cells Newson May 1, 2024 at 5:00 pm
When the team transplanted bone marrow stem cells from mice carrying a hereditary ... may also inadvertently be why cutting-edge cell therapies cause an increased risk of rhythm disorders ...
- BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technologyon April 30, 2024 at 5:30 am
Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — ...
- Accessible Cell Therapies for Alzheimer's and Parkinson's Diseaseon April 25, 2024 at 10:21 pm
Researchers have now potentially advanced the accessible personalized cell-based therapies for Alzheimer's and Parkinson's diseases.
- Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Productson April 25, 2024 at 4:00 am
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations ...
- Device improves stem cell generation and chance for accessible Alzheimer’s cell therapyon April 24, 2024 at 1:58 pm
Engineering the transformation from regular cells into neural stem cells is in effect a ... “This marks a step towards making personalized cell-based therapies for Alzheimer's and Parkinson's ...
- New device improves stem cell generation and chance for accessible Alzheimer's cell therapyon April 24, 2024 at 12:11 pm
Researchers in Sweden say they have improved on a technique for converting regular skin cells into neural stem cells—an advance that they say helps close the gap for accessible personalized cell-based ...
- Genetically engineering a treatment for incurable brain tumorson April 22, 2024 at 12:07 pm
Scientists are developing and validating a patent-pending novel immunotherapy to be used against glioblastoma brain tumors. Glioblastomas are almost always lethal with a median survival time of 14 ...
- Early Data Indicate Cell Therapies Could ‘Reset the Clock’ in Parkinson’son April 21, 2024 at 9:03 pm
A one-time treatment for Parkinson’s disease could be a ‘market changer,’ experts told BioSpace, adding that cell therapies could limit the adverse effects seen with current drugs.
via Bing News